Abstracts Accepted at EANM and IPET Conferences Comparing Seracam®
to Standard of Care Nuclear Medicine Imaging

London, UK and Kuala Lumpur, Malaysia, 1 July 2024. Serac Imaging Systems Limited ("Serac Imaging Systems" or "the Company"), the medtech company developing a portable hybrid gamma-optical camera for medical imaging, and the University of Malaya Medical Centre, today announce that abstracts related to two ongoing clinical trials taking place in Malaysia using Seracam® have been accepted for presentation at key scientific meetings later this year.

One abstract, which has been accepted as a poster presentation at the **European Association of Nuclear Medicine (EANM)** Congress 2024 taking place from 19-23 October 2024 in Hamburg, presents initial results comparing small organ imaging using Seracam with conventional standard of care gamma camera imaging. This is authored by Intan Noorliyana Md Musidek, Aik Hao Ng, and Mohammad Nazri Md Shah of the Faculty of Medicine at the University of Malaya, Chai Hong Yeong from the Faculty of Health and Medical Sciences, Taylor's University, Malaysia and Alan C. Perkins from the Radiological Sciences department, School of Medicine, University of Nottingham, UK, entitled:
"Small Field-of-View Imaging Using a Hybrid Optical-Gamma Camera: Specifications and First Clinical Results"

The other reports the first results using Seracam in image guided surgery, comparing the detection of sentinel lymph nodes in biopsy procedures in patients with breast cancer with standard gamma probe detection and has been accepted as an oral presentation at the **International Conference on Hybrid Imaging (IPET)** 2024 taking place from 7-11 October 2024 in Vienna. The authors are Intan Noorliyana Md Musidek, Aik Hao Ng, Mohammad Nazri Md Shah from the Faculty of Medicine, University of Malaya; Chai Hong Yeong from the Faculty of Health and Medical Sciences, Taylor's University, Malaysia and Alan C. Perkins from the Radiological Sciences department, School of Medicine, University of Nottingham, UK and is titled:
"First use of Seracam hybrid optical-gamma camera for sentinel lymph node imaging in breast cancer management"

Commenting on the acceptance of these abstracts, **Mark Rosser, Chief Executive of Serac Imaging Systems** said:

"Dr Ng and his team in Malaysia are reporting encouraging early results using the camera in these studies and we look forward to the presentation for the first time of clinical evaluation of scans using the camera at these prestigious meetings. Improving patient care and outcomes is central to our work and we hope these clinical studies will demonstrate Seracam's potential in both small organ imaging and image guided surgery."

- ENDS -

For more information, please contact:

Mark Rosser, Chief Executive Officer
+44 (0)20 8948 0000
info@seraclifesciences.com

Francetta Carr, Communications
+44 (0)7711 010 820
francettacarr@seraclifesciences.com

Notes to Editors

About Serac Imaging Systems and Seracam®
Serac Imaging Systems Ltd is a medtech company developing a portable hybrid gamma-optical camera for medical imaging. Our lead product is Seracam® which is in development to bring the benefits of high-resolution molecular imaging to a patient's bedside, instead of being confined for use in a hospital's nuclear medicine imaging department. A further unique feature of this technological approach is the overlay of a gamma image with an optical image of the same anatomical location under examination. Such portable and enhanced imaging technology has the potential to help clinicians make better, more informed and more timely treatment decisions.

Seracam® is a UK and EU registered trademark. Serac Imaging Systems Ltd is a wholly owned subsidiary of Serac Life Sciences Limited.

For further details, please see www.seracimagingsystems.com

Seracam® is for investigational use only and has not been cleared or approved by the FDA or UK and European regulatory authorities.

About molecular imaging
Molecular imaging is a type of medical imaging that provides unique insights into what is happening inside the body at the cellular and molecular level helping physicians to deliver personalised medicine by delivering the right treatment to the right patient at the right time. Unlike other medical imaging technologies such as x-rays, computed tomography (CT) and ultrasound (US) which provide structural images, molecular imaging allows physicians to see how cells, tissues and organs are functioning and to measure chemical and biological processes without having to resort to biopsy or surgery.

About EANM 2024: https://eanm24.eanm.org/

About IPET 2024: https://www.iaea.org/events/ipet-2024